Coordinador de Grupo
Guillermo Ruiz Irastorza
Doctor en Medicina
Profesor titular Unidad Docente Facultad de Medicina y Enfermería de la UPV/EHU, Dpto. Medicina
OSI Eskerraldea Enkarterri Cruces
Contacto
(0034) 94 600 6000
Miembros del Grupo
Monika Ferreiro Montenegro
Cristina González de Echevarri Pérez de Heredia
Daniel Martín Iglesias
Ioana Ruiz Arruza
Beatriz Ruiz Estevez
Amaia Ugarte Nuñez
Líneas de Investigación
Análisis del riesgo vascular.
Arteriopatía subclínica en el LES y el SAF.
Determinantes genéticos de trombosis en pacientes con anticuerpos antifosfolípido.
Impacto de los corticoides en el pronóstico del lupus.
Actividades del Grupo

Nuestro grupo de investigación desarrolla su actividad en el seno de la Sección de Enfermedades Autoinmunes del Servicio de Medicina Interna del Hospital Universitario Cruces. Acumulamos una dilatada experiencia clínica con pacientes afectos de lupus eritematoso sistémico (LES), síndrome antifosfolípido (SAF), esclerosis sistémica, síndrome de Sjögren y otras enfermedades autoinmunes. Somos una Unidad referente a nivel de la Comunidad Autónoma Vasca y desarrollamos, además, una intensa labor docente en este campo, contribuyendo a la formación específica de residentes de diversos hospitales españoles. Pertenecemos desde su constitución inicial al Grupo de  Enfermedades Autoinmunes Sistémicas (GEAS) de la Sociedad Española de Medicina Interna (SEMI), con plena implicación tanto en la organización de programas formativos como en el desarrollo de proyectos de investigación multicéntricos, algunos de los cuales lideramos.

Como Unidad integrada en un Hospital Universitario de tercer nivel y con especial dedicación a la medicina de alta complejidad, entendemos que la investigación está íntimamente ligada a nuestra actividad clínica. De hecho, la enfocamos como una herramienta que permite responder preguntas relacionadas con la práctica diaria, con una traslación inmediata a la aplicación específica en nuestros pacientes.

En el capítulo investigador somos un grupo consolidado en el campo del LES y SAF. Nuestra investigación se centra fundamentalmente en aspectos clínicos y se basa en la recogida de datos observacionales. Dada la relativa rareza de estas enfermedades y su heterogeneidad, los estudios de cohortes prospectivas son una herramienta de investigación habitual en este campo, de hecho gran parte de la práctica clínica en estos pacientes está basada en estudios observacionales.

De nuestras contribuciones, queremos destacar los estudios que han identificado el SAF como un factor pronóstico adverso en pacientes con LES; los que han establecido los importantes efectos beneficiosos a largo plazo de los antipalúdicos en el lupus, incluyendo una mayor supervivencia; los que han definido el nivel de anticoagulación ideal en el SAF; o los que han contribuido a clarificar el papel de la vitamina D en el lupus.

En este momento tenemos en marcha líneas activas que se centran, entre otros aspectos, en el análisis del riesgo vascular y la arteriopatía subclínica en el LES y el SAF, en los determinantes genéticos de trombosis en pacientes con anticuerpos antifosfolípido o en el impacto de los corticoides en el pronóstico del lupus.

Mantenemos desde hace más de 10 años una colaboración estable con el grupo del Dr. Munther Khamashta, que dirige la Lupus Research Unit del St. Thomas' Hospital de Londres. Somos el único grupo español miembro de pleno derecho de SLICC (Systemic Lupus International Collaborating Clinics), grupo internacional de investigación en red que reúne a muchos de los principales investigadores internacionales en el campo del lupus. Formamos parte de los grupos de investigación de lupus, esclerodermia, vasculitis y terapias biológicas (BIOGEAS) del GEAS, y coordinamos el Registro Español de Lupus Eritematoso Sistémico (RELES), la primera cohorte de incepción a nivel nacional, que cuenta ya con más de 150 pacientes en seguimiento prospectivo. Igualmente, compartimos proyectos con el grupo liderado por la Profesora Ana Zubiaga, del Departamento de Genética, Antropología física y Fisiología animal de la UPV/EHU. Más recientemente, nos hemos sumado como colaboradores a los estudios genéticos multicéntricos en el campo de la esclerosis sistémica y las vasculitis que lidera el Dr. Javier Martín, del Instituto de Parasitología y Biomedicina López-Neyra de Granada.

Proyectos Activos:

  • Factores pronósticos en el lupus eritematoso sistémico. Cohorte observacional lupus-cruces
  • Prevalencia y factores de riesgo de enfermedad cardiovascular en el lupus eritematoso sistémico
  • Estudio de las manifestaciones neuropsiquiátricas en el lupus
  • Variables asociadas al riesgo de neoplasias en el lupus eritematoso sistémico
  • Estudio de la frecuencia y factores predictores de toxicidad retiniana en pacientes con lupus en tratamiento con antipalúdicos
  • Definición y validación de escalas de actividad en  lupus
  • Identificación de variables predictivas de trombosis en individuos con anticuerpos antifofolípido
  • Identificación de genes de susceptibilidad al síndrome antifosfolípido.
  • Prevalencia y factores de riesgo de enfermedad cardiovascular en el síndrome antifosfolípido
  • Factores pronósticos en el la esclerosis sistemica
  • Factores pronósticos en las miopatías inflamatorias
  • Factores pronósticos en las vasculitis sistémicas
  • Identificación de genes de susceptibilidad a la enfermedad de behçet
  • Eficacia y efectos adversos de los tratamientos biológicos en las enfermedades autoinmunes sistémicas
  • Estudio de los factores causales y pronósticos de preeclampsia
  • Estudio de las complicaciones y factores pronósticos en el embarazo de mujeres con enfermedades autoinmunes sistémicas
Publicaciones Científicas

Costedoat-Chalumeau N, Houssiau F, Izmirly P, Le Guern V, Navarra S, Jolly M, et al. A Prospective International Study on Adherence to Treatment in 305 Patients With Flaring SLE: Assessment by Drug Levels and Self-Administered Questionnaires. Clin. Pharmacol. Ther. 2018; 103(6): 1074 - 1082. FI: 6,544(Q1). DOI: 10.1002/cpt.885.

Schreiber K, Sciascia S, de Groot PG, Devreese K, Jacobsen S, Ruiz-Irastorza G, et al. Antiphospholipid syndrome. Nat. Rev. Dis. Primers. 2018; 4: 17103. FI: 16,071(Q1). DOI: 10.1038/nrdp.2017.103.

Berasategui B, Fonollosa A, Artaraz J, Ruiz-Arruza I, Rios J, Matas J, et al. Behavior of hyperreflective foci in non-infectious uveitic macular edema, a 12-month follow-up prospective study. BMC Ophthalmol. 2018; 18: 179. FI: 1,770(Q3). DOI: 10.1186/s12886-018-0848-5.

Hanly JG, Li QJ, Su L, Urowitz MB, Gordon, C, Bae, SC, et al. Cerebrovascular Events in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. Arthritis Care Res (Hoboken). 2018; 70(10): 1478 - 1487. FI: 4,149(Q2). DOI: 10.1002/acr.23509.

Sevim E, Zisa DF, Andrade D, Pengo V, Tektonidou M, Ugarte A, et al. Clinical and Laboratory Characteristics of Persistently Antiphospholipid Antibody Positive Patients: Retrospective Results from Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) Clinical Database and Repository ("Registry"). Arthritis Rheumatol.. 2018; 70(9). MEETING ABSTRACT.

Zabala A, Salgueiro M, Saez-Atxukarro O, Ballesteros J, Ruiz-Irastorza G, Segarra R. Cognitive Impairment in Patients With Neuropsychiatric and Non-neuropsychiatric Systemic Lupus Erythematosus: A Systematic Review and Meta-analysis. J. Int. Neuropsychol. Soc. 2018; 24(6): 629 - 639. FI: 2,777(Q2). DOI: 10.1017/S1355617718000073.

Ugarte A, Porta S, Rios R, Martinez-Zapico A, Ortego-Centeno N, Agesta N, et al. Combined mepacrine-hydroxychloroquine treatment in patients with systemic lupus erythematosus and refractory cutaneous and articular activity. Lupus. 2018; 27(10): 1718 - 1722. FI: 2,969(Q3). DOI: 10.1177/0961203318768877.

Ruiz-Irastorza G, Ugarte A, Ruiz-Arruza I, Erdozain JG, Gonzalez-Echavarri C, Soto A. Comment on: The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults. RHEUMATOLOGY. 2018; 57(8): 1501 - 1502. FI: 5,245(Q1). DOI: 10.1093/rheumatology/key168. LETTER.

Legge A, Kirkland S, Rockwood K, Andreou P, Bae SC, Gordon C, et al. Construction and Validation of a Frailty Index As a Novel Health Measure in Systemic Lupus Erythematosus. Arthritis Rheumatol. 2018; 70(9). MEETING ABSTRACT.

Barber MRW, Hanly JG, Su L, Urowitz MB, Pierre YS, Romero-Diaz J, et al. Economic Evaluation of Lupus Nephritis in the Systemic Lupus International Collaborating Clinics Inception Cohort Using a Multistate Model Approach. Arthritis Care Res (Hoboken). 2018; 70(9): 1294 - 1302. FI: 4,149(Q2). DOI: 10.1002/acr.23480.

Gomez-Rubio J, Barcena-Atalaya A, Ruiz-Irastorzac G. Extraparotidal low grade follicular lymphoma associated with primary Sjogren's syndrome. Med. Clin. 2018; 150(5): 204 - 205. FI: 1,168(Q3). DOI: 10.1016/j.medcli.2017.06.056. LETTER.

Sevim E, Unlu O, Andrade D, Banzato A, Tektonidou M, Ugarte A, et al. First and Recurrent Thrombosis Risk after 1897 Patient-Years of Follow-up: Prospective Results from Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) Clinical Database and Repository ("Registry"). Arthritis Rheumatol.. 2018; 70(9). FI: 7,871(Q1). DOI: ABSTRACT.

Rubio-Rivas M, Corbella X, Pestana-Fernandez M, Tolosa-Vilella C, Guillen-del Castillo A, Colunga-Arguelles D, et al. First clinical symptom as a prognostic factor in systemic sclerosis: results of a retrospective nationwide cohort study. Clin. Rheumatol.. 2018; 37(4): 999 - 1009. FI: 2,141(Q3). DOI: 10.1007/s10067-017-3936-7.

Little J, Parker B, Lunt M, Hanly JG, Urowitz MB, Clarke AE, et al. Glucocorticoid use and factors associated with variability in this use in the Systemic Lupus International Collaborating Clinics Inception Cohort. RHEUMATOLOGY. 2018; 57(4): 677 - 687. FI: 5,245(Q1). DOI: 10.1093/rheumatology/kex444.

Ugarte A, Danza A, Ruiz-Irastorza G. Glucocorticoids and antimalarials in systemic lupus erythematosus: an update and future directions. Curr. Opin. Rheumatol. 2018; 30(5): 482 - 489. FI: 4,277(Q1). DOI: 10.1097/BOR.0000000000000527. REVIEW.

Mari-Alfonso B, Simeon-Aznar CP, Guillen-Del Castillo A, Rubio-Rivas M, Trapiella-Martinez L, Todoli-Parra JA, et al. Hepatobiliary involvement in systemic sclerosis and the cutaneous subsets: Characteristics and survival of patients from the Spanish RESCLE Registry. Semin. Arthritis Rheum. 2018; 47(6): 849 - 857. FI: 4,356(Q1). DOI: 10.1016/j.semarthrit.2017.10.004. REVIEW.

Gonzalez-Echavarri C, Capdevila O, Espinosa G, Suarez S, Marin-Ballve A, Gonzalez-Leon R, et al. Infections in newly diagnosed Spanish patients with systemic lupus erythematosus: data from the RELES cohort. Lupus. 2018; 27(14): 2253 - 2261. FI: 2,969(Q3). DOI: 10.1177/0961203318811598.

Sanchez-Cano D, Ortego-Centeno N, Callejas JL, Follonosa-Pla V, Rios-Fernandez R, Tolosa-Vilella C, et al. Interstitial lung disease in systemic sclerosis: data from the spanish scleroderma study group. Rheumatol. Int. 2018; 38(3): 363 - 374. FI: 1,952(Q4). DOI: 10.1007/s00296-017-3916-x.

Marquez A, Kerick M, Zhernakova A, Gutierrez-Achury J, Chen WM, Onengut-Gumuscu S, et al. Meta-analysis of Immunochip data of four autoimmune diseases reveals novel single-disease and cross-phenotype associations. Genome Med. 2018; 10: 97. FI: 8,898(Q1). DOI: 10.1186/s13073-018-0604-8.

Sevim E, Andrade D, Banzato A, Tektonidou M, Ugarte A, Chighizola CB, et al. Pregnancy Outcomes of Antiphospholipid Antibody Positive Patients: Prospective Results from Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) Clinical Database and Repository ("Registry"). Arthritis Rheumatol.. 2018; 70(9). MEETING ABSTRACT.

Hanly JG, Li QJ, Su L, Urowitz M, Gordon C, Bae SC, et al. Psychosis in Systemic Lupus Erythematosus: Results from an International, Inception Cohort Study. Arthritis Rheumatol. 2018; 70(9). MEETING ABSTRACT.

Ruiz-Arruza I, Lozano J, Cabezas-Rodriguez I, Medina JA, Ugarte A, Erdozain JG, et al. Restrictive Use of Oral Glucocorticoids in Systemic Lupus Erythematosus and Prevention of Damage Without Worsening Long-Term Disease Control: An Observational Study. Arthritis Care Res (Hoboken). 2018; 70(4): 582 - 591. FI: 4,149(Q2). DOI: 10.1002/acr.23322.

Isenberg D, Sturgess J, Allen E, Aranow C, Askanase A, Sang-Cheol B, et al. Study of Flare Assessment in Systemic Lupus Erythematosus Based on Paper Patients. Arthritis Care Res (Hoboken). 2018; 70(1): 98 - 103. FI: 4,149(Q2). DOI: 10.1002/acr.23252.

Tani C, Elefante E, Martin-Cascón M, Belhocine M, Lavilla-Olleros C, Vagelli R, et al. Tacrolimus in non-Asian patients with SLE: a real-life experience from three European centres. Lupus Sci Med. 2018; 5(1): e000274. FI: (Q). DOI: 10.1136/lupus-2018-000274.

Aringer M, Costenbader K, Brinks R, Boumpas D, Daikh D, Jayne D, et al. Validation of New Systemic Lupus Erythematosus Classification Criteria. Arthritis Rheumatol. 2018; 70(9). MEETING ABSTRACT.

Rodríguez-Carballeira M, Solans R, Larrañaga JR, García-Hernández FJ, Rios-Fernández R, Nieto J, et al. Venous thrombosis and relapses in patients with Behçet's disease. Descriptive analysis from Spanish network of Behçet's disease (REGEB cohort). Clin Exp Rheumatol. 2018; 36(6 Suppl 115): 40 - 44. FI: 3,201(Q2). DOI: ABSTRACT.

Amengual O, Forastiero R, Sugiura-Ogasawara M, Otomo K, Oku K, Favas C, et al. Evaluation of phosphatidylserine-dependent antiprothrombin antibody testing for the diagnosis of antiphospholipid syndrome:results of an international multicentre study. Lupus. 2017;26:266-76. FI:2,454(Q3). DOI:10.1177/0961203316660203.

Arandia NI, Simeon-Aznar CP, del Castillo AG, Arguelles DC, Rubio-Rivas M, Martinez LT, et al; RESCLE Investigators, Autoimmune D. Influence of antibody profile in clinical features and prognosis in a; cohort of Spanish patients with systemic sclerosis. Clin Exp Rheumatol. 2017; 35:98-105. FI:2,634(Q3).

Bernatsky S, Ramsey-Goldman R, Petri M, Urowitz MB, Gladman DD, Fortin PF, et al. Breast cancer in systemic lupus. Lupus. 2017;26:311-5. FI:2,454(Q3). DOI:10.1177/0961203316664595.

Bernatsky S, Urowitz M, Hanly J, Clarke A, Gordon C, Romera-Diaz J, et al. Cancer in Systemic Lupus Erythematosus: Results from the Systemic Lupus International Collaborating Clinics Inception Cohort. J Rheumatol. 2017;44:857-8. FI:3,150(Q2). ABSTRACT

Bernatsky S, Urowitz M, Hanly JG, Clarke AE, Fritzler MJ, Gordon C, et al. Cancer in an SLE Inception Cohort:Smoking May out-Perform Tumor Markers;As a Risk Predictor. Arthritis Rheumatol. 2017;69:1606. FI:6,918(Q1). ABSTRACT

Bossini-Castillo L, Campillo-Davó D, López-Isac E, Carmona FD, Simeon CP, Carreira P, et al. An MIF Promoter Polymorphism Is Associated with Susceptibility to Pulmonary Arterial Hypertension in Diffuse Cutaneous Systemic Sclerosis. J Rheumatol. 2017;44:1453-7. FI:3,150(Q2). DOI: 10.3899/jrheum.161369.

Cabezón I, Barreiro G, Egurbide MV. Parsonage-Turner syndrome: A case report. Reumatol Clin. 2017;13:60-1. DOI: 10.1016/j.reuma.2016.03.001.

Canora J, García M, Mitjavila F, Espinosa G, Suárez S, González-León R, et al. Clinical characteristics during diagnosis of a prospective cohort of patients with systemic lupus erythematosus treated in Spanish; Departments of Internal Medicine: The RELES study. Rev Clin Esp. 2017;217:7-14. FI:0,971(Q3). DOI:10.1016/j.rce.2016.09.006.

Choi MY, Clarke AE, St Pierre Y, Hanly JG, Urowitz MB, Romero-Diaz J, et al. The prevalence and determinants of anti-DFS70 autoantibodies in an international inception cohort of systemic lupus erythematosus patients. Lupus. 2017;26:1051-9. FI:2,454(Q3). DOI:10.1177/0961203317692437.

Erdozain JG, Villar I, Nieto J, Ruiz-Arruza I, Ruiz-Irastorza G. Predictors of peripheral arterial disease in SLE change with patient's age. Lupus Sci Med. 2017;4:e000190. DOI:10.1136/lupus-2016-000190.

Erdozain JG, Villar I, Nieto J, Ruiz-Arruza I, Pijoan JI, Ruiz-Irastorza G. Predictors of arterial vascular events in a cohort of systemic lupus erythematosus. Ann Rheum Dis. 2017;76:593. FI:12,811(Q1). DOI:10.1136/annrheumdis-2017-eular.3013. ABSTRACT

Ferreira I, Croca S, Raimondo MG, Matharu M, Miller S, Giles I, et al. Nitrated nucleosome levels and neuropsychiatric events in systemic lupus erythematosus; a multi-center retrospective case-control study. Arthritis Res Ther. 2017;19:287. FI:4,121(Q2). DOI:10.1186/s13075-017-1495-6.

Freire M, Rivera A, Sopena B, Vilella CT, Guillen-Del Castillo A, Arguelles DC, et al. Clinical and epidemiological differences between men and women with systemic sclerosis: a study in a Spanish systemic sclerosis cohort and literature review. Clin Exp Rheumatol. 2017;35: 89-97. FI:2,634(Q3).

Jackson WG, Oromendia C, Unlu O, Erkan D, DeSancho MT. Antiphospholipid syndrome alliance for clinical trials and international network. Recurrent thrombosis in patients with antiphospholipid antibodies and arterial thrombosis on antithrombotic therapy. Blood Adv. 2017;1:2320-4. FI: (Q). DOI: 10.1182/bloodadvances.2017008185.

Márquez A, Cordero-Coma M, Martín-Villa JM, Gorroño-Echebarría MB, Blanco R, Díaz Valle D, et al. New insights into the genetic component of non-infectious uveitis through an Immunochip strategy. J Med Genet. 2017;54:38-46. FI:5,451(Q1). DOI:10.1136/jmedgenet-2016-104144.

Rubio-Rivas M, Simeon-Aznar CP, Velasco C, Mari-Alfonso B, Espinosa G, Corbella X, et al. Changes in the pattern of death of 987 patients with systemic sclerosis from 1990 to 2009 from the nationwide Spanish Scleroderma Registry (RESCLE). Clin Exp Rheumatol. 2017;35:40-7. FI:2,634(Q3).

Ruiz-Irastorza G, Ugarte A, Terrier CSP, Lazaro E, Iza A, Couzi L, et al. Repeated pulses of methyl-prednisolone with reduced doses of prednisone improve the outcome of class III, IV and V lupus nephritis: An observational comparative study of the Lupus-Cruces and lupus-Bordeaux cohorts. Autoimmun Rev. 2017;16:826-32. FI:8,961(Q1). DOI:10.1016/j.autrev.2017.05.017.

Sevim E, Andrade D, Banzato A, Branch DW, Cervera R, de Jesus GR, et al. Antiphospholipid syndrome alliance for clinical trials and international networking (aps action) clinical database and repository analysis pregnancy outcomes since inception. Arthritis Rheumatol. 2017;69:12. FI:6,918(Q1). ABSTRACT

Tani C, Martin-Cascon M, Belhocine M, Vagelli R, Stagnaro C, Ruiz-Irastorza G, et al. Tacrolimus in non-asian systemic lupus erythematosus patients: areal-life experience from three european centers. Arthritis Rheumatol. 2017;69:2608. FI:6,918(Q1). ABSTRACT

Tedeschi S, Johnson S, Boumpas D, Daikh D, Diamond B, Dorner T, et al. Multicriteria decision analysis for developing new classification criteria for systemic lupus erythematosus. Ann Rheum Dis. 2017;76:50. FI:12,811(Q1). DOI:10.1136/annrheumdis-2017-eular.5464. ABSTRACT

Tedeschi SK, Johnson S, Boumpas D, Daikh DI, Diamond B, Doerner T, et al. A Multicriteria Decision Analysis for the Development of New Systemic; Lupus Erythematosus Classification Criteria. Arthritis Rheumatol. 2017;69:1589. FI:6,918(Q1). ABSTRACT

Trapiella-Martinez L, Diaz-Lopez JB, Caminal-Montero L, Tolosa-Vilella C, Castillo AGD, Colunga-Arguelles D, et al; Autoimmune Diseases Study Grp GEAS, Spanish Soc Internal Med SEMI. Very early and early systemic sclerosis in the Spanish scleroderma; Registry (RESCLE) cohort. Autoimmun Rev. 2017;16:796-802. FI:8,961(Q1). DOI:10.1016/j.autrev.2017.05.013.

Unlu O, Andrade D, Banzato A, Branch DW, Fortin PR, Gerosa M, et al; APS ACTION. Antiphospholipid Syndrome Alliance for Clinical Trials & International; Networking (APS ACTION) Clinical Database and Repository ("Registry"); Analysis: First and Recurrent Thrombosis Risk after 1201 Patient-Years; of Follow-up. Arthritis Rheumatol. 2017;69:2760. FI: 6,918(Q1). ABSTRACT

Brito-Zeron P, Bosch X, Perez-de-Lis M, Perez-Alvarez R, Fraile G, Gheitasi H, et al. Infection is the major trigger of hemophagocytic syndrome in adult patients treated with biological therapies. Semin Arthritis Rheum. 2016;45:391-399. FI:4,498(Q1). DOI:10.1016/j.semarthrit.2015.07.004.

Costedoat-Chalumeau N, Houssiau F, Izmirly P, Le Guern V, Navarra S, Jolly M, et al. Adherence to hydroxychloroquine as assessed by measurements of drug and metabolite blood levels in an international prospective study of sle patients in flare. Clin Exp Rheumatol. 2016;34: 41. FI:2,634(Q3). ABSTRACT

Danza A, Grana D, Goni M, Vargas A, Ruiz-Irastorza G. Hydroxychloroquine for autoimmune diseases. Rev Medica Chile. 2016;144:232-40. FI:0,519(Q4). DOI:10.4067/S0034-98872016000200012.

Danza A, Ruiz-Irastorza G, Khamashta M. El embarazo en las enfermedades autoinmunes sistémicas: mitos, certezas y dudas. Med Clin (Barc). 2016;147:306-12. FI:1,125(Q3). DOI:10.1016/j.medcli.2016.03.019. ABSTRACT

Del Pino-Sedeño T, Trujillo-Martín MM, Ruiz-Irastorza G, Cuellar-Pompa L, de Pascual-Medina AM, Serrano-Aguilar P; Spanish Systemic Lupus Erythematosus CPG Development Group. Effectiveness of Nonpharmacologic Interventions for Decreasing Fatigue in Adults With Systemic Lupus Erythematosus: A Systematic Review. Arthritis Care Res (Hoboken). 2016;68:141-8. FI:3,319(Q2). DOI:10.1002/acr.22675.

Del Pozo R, Quezada-Loaiza CA, Barbera JA, Dos-Subira L, Molina-Ferragut L, Castillo-Palma MJ, et al. Influence of age at diagnosis in the prognostic evaluation of patients with idiopathic pulmonary arterial hypertension and associated to connective tissue disease: insights of Spanish Registry (REHAP). Eur Heart J. 2016;37:363. FI:19,651(Q1). ABSTRACT

Fonollosa A, Llorenç V, Artaraz J, Jimenez B, Ruiz-Arruza I, Agirrebengoa K, et al. Safety and efficacy of intravitreal dexamethasone implants in the management of macular edema secondary to infectious uveitis. Retina. 2016;36:1778-85. FI:3,700(Q1). DOI:10.1097/IAE.0000000000001001.

Fonollosa A, Martinez-Indart L, Artaraz J, Martinez-Berriotxoa A, Agirrebengoa K, Garcia M, et al. Clinical Manifestations and Outcomes of Syphilis-associated Uveitis in Northern Spain. Ocul Immunol Inflamm. 2016;24:147-52. FI:2,453(Q2). DOI:10.3109/09273948.2014.943349.

Fonollosa A, Valsero S, Artaraz J, Ruiz-Arruza I. Dexamethasone intravitreal implants in the management of tubercular multifocal serpiginoid choroiditis. J Ophthalmic Inflamm Infect. 2016;6:31. DOI:10.1186/s12348-016-0101-4.

Gonzalez-Echavarri C, Ugarte A, Ruiz-Irastorza G. Rituximab-refractory lupus nephritis successfully treated with belimumab.Clin Exp Rheumatol. 2016;34:355-6. FI:2,634(Q3).

Hanly JG, O'Keeffe AG, Su L, Urowitz MB, Romero-Diaz J, Gordon C, et al. The frequency and outcome of lupus nephritis: results from an international inception cohort studyRheumatology (Oxford). 2016;55:252-62. FI:4,818(Q1). DOI:10.1093/rheumatology/kev311.

Hanly JG, Su L, Urowitz MB, Romero-Diaz J, Gordon C, Bae SC, et al. A Longitudinal Analysis of Outcomes of Lupus Nephritis in an International Inception Cohort Using a Multistate Model Approach.Arthritis Rheumatol. 2016;68:1932-44. FI:6,918(Q1). DOI:10.1002/art.39674.

Kaul A, Gordon C, Crow MK, Touma Z, Urowitz MB, van Vollenhoven R, et al. Systemic lupus erythematosus. Nat Rev Dis Primers. 2016;2:16039. FI:6,389(Q1). DOI:10.1038/nrdp.2016.39.

Legault KJ, Ugarte A, Crowther MA, Ruiz-Irastorza G. Prevention of Recurrent Thrombosis in Antiphospholipid Syndrome: Different from the General Population?. Curr Rheumatol Rep. 2016;18:26. FI:2,865(Q2). DOI:10.1007/s11926-016-0573-0.

Lopez-Isac E, Campillo-Davo D, Bossini-Castillo L, Guerra SG, Assassi S, Simeon CP, et al; Spanish Scleroderma Grp. Influence of TYK2 in systemic sclerosis susceptibility: a new locus in the IL-12 pathway. Ann Rheum Dis. 2016;75:1521-6. FI:12,811(Q1). DOI:10.1136/annrheumdis-2015-208154.

Lopez-Isac E, Martin JE, Assassi S, Simeon CP, Carreira P, Ortego-Centeno N, et al; Spanish Scleroderma Grp. IRF4 Newly Identified as a Common Susceptibility Locus for Systemic Sclerosis and Rheumatoid Arthritis in a Cross-Disease Meta-Analysis of Genome-Wide Association Studies. Arthritis Rheumatol. 2016;68:2338-44. FI:6,918(Q1). DOI:10.1002/art.39730.

Ochoa E, Iriondo M, Manzano C, Fullaondo A, Villar I, Ruiz-Irastorza G,et al. LDLR and PCSK9 Are Associated with the Presence of Antiphospholipid Antibodies and the Development of Thrombosis in aPLA Carriers. PLoS One. 2016;11:e0146990 . FI:2,806(Q1). DOI:10.1371/journal.pone.0146990.

Porta S, Martinez A, Ugarte A, Rios R, Ortego N, Ruiz-Irastorza G. Response to a combined hydroxychloroquine-quinacrine treatment in sle with cutaneous and/or joint disease. Clin Exp Rheumatol. 2016; 34:14. FI:2,634(Q3). ABSTRACT

Rodriguez Huerta MD, Trujillo-Martin MM, Rua-Figueroa I, Cuellar-Pompa L, Quiros-Lopez R, Serrano-Aguilar P; Spanish SLE CPG Dev Grp. Healthy lifestyle habits for patients with systemic lupus erythematosus: A systemic review. Semin Arthritis Rheum. 2016;45:463-70. FI:4,498(Q1). DOI:10.1016/j.semarthrit.2015.09.003.

Ruiz-Irastorza G, Garcia M, Espinosa G, Caminal L, Mitjavila F, González-León R, et al. First month prednisone dose predicts prednisone burden during the following 11 months: an observational study from the RELES cohort. Lupus Sci Med. 2016;3:e000153. DOI:10.1136/lupus-2016-000153.

Ruiz-Irastorza G, García M, Espinosa G, Cabezas-Rodríguez I, Mitjavila F, González-León R, et al;RELES, Autoimmune Diseases Study Group GEAS. Patterns of drug therapy in newly diagnosed Spanish patients with systemic lupus erythematosus. Clin Exp Rheumatol. 2016;34:466-72. FI:2,634(Q3).

Ruiz-Irastorza G, García M, Espinosa G, Cabezas-Rodríguez I, Mitjavila F, González-León R, et al; RELES, Autoimmune Diseases Study Group GEAS. Patterns of drug therapy in newly diagnosed Spanish patients with systemic lupus erythematosus. Clin Exp Rheumatol. 2016;34:466-72. FI:2,634(Q3).

Rydén-Aulin M, Boumpas D, Bultink I, Callejas Rubio JL, Caminal-Montero L, Castro A, et al. Off-label use of rituximab for systemic lupus erythematosus in Europe. Lupus Sci Med. 2016;3:e000163. DOI:10.1136/lupus-2016-000163

Sciascia S, Branch DW, Levy RA, Middeldorp S, Pavord S, Roccatello D, et al. The efficacy of hydroxychloroquine in altering pregnancy outcome in women with antiphospholipid antibodies. Evidence and clinical judgment.Thromb Haemost. 2016;115:285-90. FI:5,627(Q1). DOI:10.1160/TH15-06-0491.

Götestam Skorpen C, Hoeltzenbein M, Tincani A, Fischer-Betz R, Elefant E, Chambers C, et al. The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann Rheum Dis. 2016;75:795-810. FI:12,811(Q1). DOI:10.1136/annrheumdis-2015-208840.

Tolosa-Vilella C, Morera-Morales L, Simeon-Aznar CP, Mari-Alfonso B, Colunga-Arguelles D, Callejas Rubio JL, et al; RESCLE Investigators, Autoimmune Dis Study Grp GEAS. Digital ulcers and cutaneous subsets of systemic sclerosis: Clinical, immunological, nailfold capillaroscopy, and survival differences in the Spanish RESCLE Registry. Semin Arthritis Rheum. 2016; 46:200-8. FI:4,498(Q1). DOI:10.1016/j.semarthrit.2016.04.007.

Trujillo-Martín MM, Rúa-Figueroa Fernández de Larrinoa I, Ruíz-Irastorza G, Pego-Reigosa JM, Sabio Sánchez JM, Serrano-Aguilar P; en nombre del Grupo Elaborador de la GPC-LES. Guía de práctica clínica para el lupus eritematoso sistémico: recomendaciones para el abordaje clínico general. Med Clin (Barc). 2016;146:413.e1-14. FI:1,125(Q3). DOI:10.1016/j.medcli.2016.01.013.

Ugarte A, Ruiz-Irastorza G. SLE: the changing prognosis.Lupus. 2016;25:1285-7. FI:2,454(Q3). DOI:10.1177/0961203316652948.

Urowitz MB, Gladman DD, Anderson NM, Su J, Romero-Diaz J, Bae SC, et al. Cardiovascular events prior to or early after diagnosis of systemic lupus erythematosus in the systemic lupus international collaborating clinics cohort. Lupus Sci Med. 2016;3:e000143. DOI:10.1136/lupus-2015-000143.

Vivero F, Gonzalez-Echavarri C, Ruiz-Estevez B, Maderuelo I, Ruiz-Irastorza G. Prevalence and predictors of valvular heart disease in patients with systemic lupus erythematosus. Autoimmun Rev. 2016;15:1134-40. FI:8,961(Q1). DOI:10.1016/j.autrev.2016.09.007.

Barber M, Hanly JG, O'Keeffe A, Su L, Urowitz M, St Pierre Y, et al. Economic Evaluation of Lupus Nephritis in an International Inception Cohort: Comparing the Hospitalization, Medication, Dialysis, and Procedure Costs of Those with and without Nephritis. Arthritis Rheumatol. 2015;67:989. FI:6,009(Q1). ABSTRACT

Bruce IN, O'Keeffe AG, Farewell V, Hanly JG, Manzi S, Su L, et al. Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort. Ann Rheum Dis. 2015;74:1706-1713. FI:12,384(Q1). DOI:10.1136/annrheumdis-2013-205171.

Choi M, Hanly JG, Urowitz M, Romero-Diaz J, Gordon C, Bae S-C, et al. The Prevalence of Anti-DFS70 Antibodies in an International Inception Cohort of Systemic Lupus Erythematosus. Arthritis Rheumatol. 2015;67(10). FI:6,009(Q1). ABSTRACT

Del Pozo R, Blanco I, Quezada CA, Lopez R, Egurbides, V, Cremer D, et al. Factors associated with operability of chronic thromboembolic pulmonary hypertension: insights of Spanish registry (REHAP). Eur Heart J. 2015;36:628. FI:15,064(Q1). ABSTRACT

Erdozain JG, Ruiz G. Metabolic syndrome in patients with systemic lupus erythematosus: Causes and consequences. Med Clin (Barc). 2015;144:309-311. FI:1,267(Q2). DOI:10.1016/j.medcli.2014.09.011. EDITORIAL MATERIAL

Gonzalez-Echavarri C, Villar I, Ugarte A, Larrieta R, Ruiz-Irastorza G. Prevalence and Significance of Persistently Positive Antiphospholipid Antibodies in Women with Preeclampsia. J Rheumatol. 2015;42:210-213. FI:3,236(Q2). DOI:10.3899/jrheum.140737.

Hanly JG, Li Q, Su L, Urowitz M, Romero-Diaz J, Gordon C, et al. The Initial Presentation of Cerebrovascular Disease Attributed to Lupus Is Most Frequent Early in the Disease Course: Results from an International, Inception Cohort Study. Arthritis Rheumatol. 2015; 67:2902. FI:6,009(Q1).

Hanly JG, Su L, Urowitz M, Romero-Diaz J, Gordon C, Bae SC, et al. A Longitudinal Analysis of Change in Lupus Nephritis in an International Inception Cohort Using a Multistate Markov Model Approach. Arthritis Rheumatol. 2015;67:3122. FI:6,009(Q1). ABSTRACT

Hanly JG, Su L, Urowitz MB, Romero-Diaz J, Gordon C, Bae S-C, et al. Mood Disorders in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. Arthritis Rheumatol. 2015;67:1837-1847. FI:6,009(Q1). DOI:10.1002/art.39111. ABSTRACT

Leon DA, Serrano A, Cordero-Coma M, Marquez A, Fonollosa A, Ruiz-Arruza I, et al. Study of association of CTLA4 gene variants to non-anterior uveitis. Tissue Antigens. 2015;86:373-376. FI:2,046(Q2). DOI:10.1111/tan.12668.

Les I, Pijoan JI, Rodriguez-Alvarez R, Ruiz-Irastorza G, Martinez-Berriotxoa A. Effectiveness and safety of medium-dose prednisone in giant cell arteritis: a retrospective cohort study of 103 patients. Clin Exp Rheumatol. 2015;33:90-97. FI:2,495(Q2).

Mucientes A, Marquez A, Cordero-Coma M, Martin-Villa JM, Gorrono-Echebarria MB, Blanco R, et al. Specific association of IL17A genetic variants with panuveitis. Brit J Ophthalmol. 2015;99:566-570. FI:3,036(Q1). DOI:10.1136/bjophthalmol-2014-306106.

Ochoa E, Martin J-E, Assassi S, Beretta L, Carreira P, Guillen A, et al. Confirmation of CCR6 as a risk factor for anti-topoisomerase I antibodies in systemic sclerosis. Clin Exp Rheumatol. 2015;33:31-35. FI:2,495(Q2).

Orbai A-M, Truedsson L, Sturfelt G, Nived O, Fang H, Alarcon GS, et al. Anti-C1q antibodies in systemic lupus erythematosus. Lupus. 2015;24:42-49. FI:2,118(Q3). DOI:10.1177/0961203314547791.

Ostensen M, Andreoli L, Brucato A, Cetin I, Chambers C, Clowse MEB, et al. State of the art: Reproduction and pregnancy in rheumatic diseases. Autoimmun Rev. 2015;14:376-386. FI:8,490(Q1). DOI:10.1016/j.autrev.2014.12.011.

Parker B, Urowitz MB, Gladman DD, Lunt M, Donn R, Bae S-C, et al. Impact of early disease factors on metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort. Ann Rheum Dis. 2015;74:1530-1536. FI:12,384(Q1). DOI:10.1136/annrheumdis-2013-203933.

Ruiz-Arruza I, Barbosa C, Ugarte A, Ruiz-Lrastorza G. Comparison of high versus low-medium prednisone doses for the treatment of systemic lupus erythematosus patients with high activity at diagnosis. Autoimmun Rev. 2015;14:875-879. FI:8,490(Q1). DOI:10.1016/j.autrev.2015.05.011.

Saez-Comet L, Simeon-Aznar CP, Perez-Conesa M, Vallejo-Rodriguez C, Tolosa-Vilella C, Iniesta-Arandia N, et al. Applying the ACR/EULAR Systemic Sclerosis Classification Criteria to the Spanish Scleroderma Registry Cohort. J Rheumatol. 2015;42:2327-2331. FI:3,236(Q2). DOI:10.3899/jrheum.150144.

Serrano-Aguilar P, Trujillo-Martin MM, Pérez de la Rosa A, Cuellar-Pompa L, Saavedra-Medina H, Linertova R, el al. Patient participation in a Clinical Guideline Development for Systemic Lupus Erythematosus. Patient Educ Couns. 2015;98:1156-1163. FI:2,232(Q2). DOI:10.1016/j.pec.2015.05.022.

Simeon-Aznar CP, Fonollosa-Pla V, Tolosa-Vilella C, Espinosa-Garriga G, Campillo-Grau M, Ramos-Casals M, et al. Registry of the Spanish Network for Systemic Sclerosis Survival, Prognostic Factors, and Causes of Death. Medicine. 2015;94(43):e1728. FI:1,206(Q3). DOI:10.1097/MD.0000000000001728.

Sturgess J, Allan E, Isenberg DA, Aranow C, Aringer M, Askanase A, et al. A Paper Patient-Based Flare Study in SLE. Arthritis Rheumatol. 2015; 67:737. FI:6,009(Q1). ABSTRACT

Ugarte A, Ruiz G. Rituximab in antiphospholipid syndrome: Always, never, sometimes?. Med Clin (Barc). 2015;144:115-117. FI:1,267(Q2). DOI:10.1016/j.medcli.2014.04.014. EDITORIAL MATERIAL

Lahera G, Bayón C, Fe Bravo-Ortiz M, Rodríguez-Vega B, Barbeito S, Sáenz M, et al. BMC Psychiatry. 2014;14:215. FI: 2,210(Q3)

Rodríguez-Carballeira M, Alba MA, Solans-Laqué R, Castillo MJ, Ríos-Fernández R, Larrañaga JR, et al; REGEB investigators. Registry of the Spanish network of Behcet's disease: a descriptive analysis of 496 patients. Clin Exp Rheumatol. 2014;32:33-9. FI: 2,724(Q2)

Gonzalez-Echavarri C, Pernas B, Ugarte A, Ruiz-Irastorza G. Severe multiorganic flare of systemic lupus erythematosus successfully treated with rituximab and cyclophosphamide avoiding high doses of prednisone. Lupus. 2014;23:323-6. FI: 2,197(Q3)

Alba MA, Velasco C, Simeón CP, Fonollosa V, Trapiella L, Egurbide MV, et al; RESCLE Registry. Early- versus Late-Onset Systemic Sclerosis Differences in Clinical Presentation and Outcome in 1037 Patients. Medicine (Baltimore). 2014;93:73-81. FI: 5,723(Q1)

Erdozain JG, Villar I, Nieto J, Ruiz-Irastorza G. Peripheral Arterial Disease in Systemic Lupus Erythematosus: Prevalence and Risk Factors. J Rheumatol. 2014;41:310-7. FI: 3,187(Q2)

Cuadrado MJ, Bertolaccini ML, Seed PT, Tektonidou MG, Aguirre A, Mico L, et al. Low-dose aspirin vs low-dose aspirin plus low-intensity warfarin in thromboprophylaxis: a prospective, multicentre, randomized, open, controlled trial in patients positive for antiphospholipid antibodies (ALIWAPAS). Rheumatology (Oxford). 2014;53:275-84. FI: 4,475(Q1)

Mayes MD, Bossini-Castillo L, Gorlova O, Martin JE, Zhou X, Chen WV, et al. Immunochip analysis identifies multiple susceptibility loci for systemic sclerosis. Am J Hum Genet. 2014;94:47-61. FI: 10,931(Q1)

Bernatsky S, Ramsey-Goldman R, Joseph L, Boivin JF, Costenbader KH, Urowitz MB, et al. Lymphoma risk in systemic lupus: effects of disease activity versus treatment. Ann Rheum Dis. 2014;73:138-42. FI: 10,377(Q1)

López-Isac E, Bossini-Castillo L, Simeon CP, Egurbide MV, Alegre-Sancho JJ, Callejas JL, et al; Spanish Scleroderma Group. A genome-wide association study follow-up suggests a possible role for PPARG in systemic sclerosis susceptibility. Arthritis Res Ther. 2014;16:R6. FI: 3,753(Q2)

Erdozain JG, Villar I, Nieto J, Ruiz-Irastorza G. Dr. Erdozain, et al reply. J Rheumatol. 2014;41:2086. FI: 3,187(Q2)

Rodriguez-Alvarez R, Goikoetxea J, Garcia M, Figueras Y, Hernandez L, Montejo M. Endovascular infections by Campylobacter: with regard to two cases. Rev Esp Quimioter. 2014;27:127-9. FI: 0,797(Q4)

Gutiérrez-Fernández A, Palomino A, González-Pinto A, Ugarte A, Hernanz M, Mendíbil B, et al. Novel association of Neuregulin 1 gene with bipolar disorder but not with schizophrenia. Schizophr Res. 2014;159:552-3. FI: 3,923(Q1)

Martin J, Ochoa E, Martin JE, Assassi S, Beretta L, Caireira P, et al. Systemic Sclerosis Patients with Antitopoisomerase Antibodies Showed Significant Association with CCR6 Polymorphisms. Arthritis Rheumatol. 2014;66:328. FI: 0,000(Q4)

Amenqual O, Forastiero R, Sugiura-Ogasawara M, Oku K, Otomo K, Alves J, et al. International multi-centre study to evaluate the clinical significance of phosphatidylserine-dependent antiprothrombin antibodies for the diagnosis of antiphospholipid syndrome. Ann Rheum Dis. 2014;73:662-3. FI: 10,377(Q1)

Saez-Comet L, Perez-Conesa M, Vallejo-Rodriguez C, Fonollosa-Pla V, Colunga-Arguelles D, Egurbide-Arberas MV, et al; RESCLE Registro Espanol Esclerod. Comparison of ACR 1980's and ACR/EULAR 2013's systemic sclerosis classification criteria in the rescle cohort. Ann Rheum Dis. 2014;73:709. FI: 10,377(Q1)

Rubio-Rivas M, Fonollosa-Pla V, Corbella-Viros X, Tolosa-Vilella C, Colunga-Argueelles D, Egurbide-Arberas MV, et al; RESCLE, Scleroderma Spanish Grp. Changes in the pattern of death in systemic sclerosis. Ann Rheum Dis. 2014;73:710. FI: 10,377(Q1)

Brito Zeron P, Caminal-Montero L, Chamorro A, de la Hera Fernandez J, Gato A, Marin-Ballve A, et al. Blocking the human b lymphocyte stimulator molecule (BLYS) using a monoclonal antibody (BELIMUMAB) in systemic lupus erythematosus: first results in real-life spanish patients with refractory disease (BIOGEAS-SEMI REGISTRY). Ann Rheum Dis. 2014;73:985. FI: 10,377(Q1)

Iniesta N, Espinosa G, Fonollosa V, Tolosa C, Egurbide MV, Saez Comet L, et al; Spanish Scleroderma Study Grp. Anti-RNA polymerase III and anti PM/SCL antibodies: prevalence and clinical associations in a large cohort of spanish patients with systemic sclerosis. Ann Rheum Dis. 2014;3:1014. FI: 10,377(Q1)

Mild M, Wallace DJ, Clarke AE, Bernatsky SR, Peschken C, Jacobsen S, et al; SLICC Grp. Patient characteristics in the Prospective International Register of Biologics in SLE (IRBIS-II): year 1 data. Scand J Rheumatol. 2014;43:61-2. FI: 2,527(Q2)

Ruiz-Irastorza G, Danza A, Perales I, Villar I, Garcia M, Delgado S, et al. Prednisone in lupus nephritis: How much is enough?. Autoimmun Rev. 2014;13:206-14. FI: 7,933(Q1)

Ruiz-Irastorza G, Danza A, Khamashta M. Treatment of systemic lupus erythematosus: Myths, certainties and doubts. Med Clin. 2013;141:533-42. FI: 1,399(Q2)

Carmen Cenit M, Marquez A, Cordero-Coma M, Gorrono-Echebarria M, Fonollose A, Adan A, et al. No Evidence of Association between Common Autoimmunity STAT4 and IL23R Risk Polymorphisms and Non-Anterior Uveitis. PLoS One 2013;8:e72892. FI: 3,730(Q1)

Hanly JG, Urowitz MB, O'Keeffe AG, Gordon C, Bae SC, Sanchez-Guerrero J, et al. Headache in Systemic Lupus Erythematosus Results From a Prospective, International Inception Cohort Study. Arthritis Rheum. 2013;65:2887-97. FI: 7,477(Q1)

Bernatsky S, Ramsey-Goldman R, Petri M, Urowitz MB, Gladman DD, Peschken C, et al: SLICC. Breast Cancer In Systemic Lupus (SLE): Do Demographic and Clinical Factors, Including DNA serology, Influence Risk?. Arthritis Rheum. 2013;65:252. FI: 7,477(Q1). ( Meeting Abstract)

Hanly JG, Urowitz MB, o'Keeffe A, Gordon C, Bae SC, Sanchez-Guerrero J, et al.``Lupus Headache'': Results From a Prospective, International, Inception Cohort Study. Arthritis Rheum. 2013;65:675-6. FI: 7,477(Q1). ( Meeting Abstract)

van Vollenhoven RF, Mild M, Doria A, Doerner T, Ferraccioli G, Houssiau F, et al;  IRBIS-EMA Grp. Off-Label Use Of Rituximab For Systemic Lupus Erythematosus in Europe: Limited Use Mostly In Refractory Patients. Arthritis Rheum. 2013;65:684. FI: 7,477(Q1). ( Meeting Abstract)

Danza A, Ruiz-Irastorza G. Infection risk in systemic lupus erythematosus patients: susceptibility factors and preventive strategies. Lupus. 2013;22:1286-94. FI: 2,783(Q2)

Martin JE, Assassi S, Diaz-Gallo LM, Broen JC, Simeon CP, Castellvi I, et al. A systemic sclerosis and systemic lupus erythematosus pan-meta-GWAS reveals new shared susceptibility loci. Hum Mol Genet. 2013;22:4021-9. FI: 7,692(Q1)

Parker B, Urowitz MB, Gladman DD, Lunt M, Bae SC, Sanchez-Guerrero J, et al. Clinical associations of the metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort. Ann Rheum Dis. 2013;72:1308-14. FI: 9,111(Q1)

Ruiz-Irastorza G, Petri M, Gordon C, Khamashta M. Managing Lupus Nephritis in Pregnant Women: Comment on the Article by Hahn et al. Arthritis Care Res. 2013;65:1391-2. FI: 3,731(Q2)

Ochoa E, Iriondo M, Bielsa A, Ruiz-Irastorza G, Estonba A,  Zubiaga AM. Thrombotic Antiphospholipid Syndrome Shows Strong Haplotypic Association with SH2B3-ATXN2 Locus. PLoS One. 2013;8:e67897. FI: 3,730(Q1)

Cénit MC, Márquez A, Cordero-Coma M, Fonollosa A, Adán A, Martínez-Berriotxoa A, et al. Evaluation of the IL2/IL21, IL2RA and IL2RB genetic variants influence on the endogenous non-anterior uveitis genetic predisposition. BMC Med Genet. 2013;14:52. FI: 2,536(Q3)

Bernatsky S, Ramsey-Goldman R, Labrecque J, Joseph L, Boivin JF, Petri M, et al. Cancer risk in systemic lupus: An updated international multi-centre cohort study. J Autoimmun. 2013;42:130-5. FI: 8,145(Q1)

Gladman DD,  Ibanez D, Ruiz I, Urowitz MB. Recommendations for Frequency of Visits to Monitor Systemic Lupus Erythematosus in Asymptomatic Patients: Data from an Observational Cohort Study. J Rheumatol. 2013;40:630-3. FI: 3,258(Q2)

Arana B, Fonollosa A, Artaraz J, Martinez-Berriotxoa A, Martinez-Alday N. Macular hole secondary to toxoplasmic retinochoroiditis. Int Ophthalmol. 2013 : -0. FI: 0,000(Q0)

Carmona DF, Martin JE, Lorenzo B, Simeon CP, Carreira PE, Callejas JL,  et al; Spanish Scleroderma Grp. The Systemic Lupus Erythematosus IRF5 Risk Haplotype Is Associated with Systemic Sclerosis. PLoS One. 2013;8:e54419. FI: 3,730(Q1)

Ramos-Casals M, Ruiz-Irastorza G, Jimenez-Alonso J, Khamashta MA. SEMI. Recommendations on the use of belimumab in systemic lupus erythematosus. GEAS-SEMI. Clinical Practice Guide. Rev Clin Esp. 2013;213:42-58. FI: 2,008(Q2)

Ramos-Casals M, Ruiz-Irastorz G, Jimenez-Alonso J, Khamashta MA, SEMI. Belimumab in systemic lupus erythematosus: a guide for its use in the daily practice. Rev Clin Esp. 2013;213:66-7. FI: 2,008(Q2)

Tessier Cloutier B, Clarke AE, Ramsey-Goldman R, Wang Y, Foulkes W, Gordon C, et al. Breast Cancer in Systemic Lupus Erythematosus. Oncology. 2013;85:117-21. FI: 2,165(Q3)

Ruiz-Irastorza G, Garmendia M, Villar I, Egurbide MV, Aguirre C. Pulmonary hypertension in systemic lupus erythematosus: prevalence, predictors and diagnostic strategy. Autoimmun Rev. 2013;12:410-5. FI: 7,975(Q1)

Guillevin L, Hunsche E, Denton CP, Krieg T, Schwierin B, Rosenberg D, et al; DUO Registry Group. Functional impairment of systemic scleroderma patients with digital ulcerations: results from the duo registry. Clin Exp Rheumatol. 2013;31(suppl 2):71-80.

Diaz-Gallo LM, Simeon CP, Broen JC, Ortego-Centeno N, Beretta L, Vonk MC, et al; Spanish Scleroderma Group. Implication of IL-2/IL-21 region in systemic sclerosis genetic susceptibility. Ann Rheum Dis. 2013;72:1233-8.

Teruel M, Simeon CP, Broen J, Carreira P, García de la Peña P, Aguirre MÁ, et al; Spanish Scleroderma Group. The role of the NLRP1 gene in systemic sclerosis: a replication study. Clin Exp Rheumatol. 2013;2(Suppl 76):187-8.

Perez-Alvarez R, Pérez-de-Lis M, Ramos-Casals M; BIOGEAS study group. Biologics-induced autoimmune diseases. Curr Opin Rheumatol. 2013;25:56-64.

Tesis

Autor/a: Guillermo Barreiro. Título: Insuficiencia renal en el mieloma múltiple. Análisis de factores pronósticos. Directores: Dr. Guillermo Ruiz Irastorza.